Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 901 results for "sanofi"

Sanofi India Q2 net up 33% at Rs 85 crore
Money Control

Sanofi India Q2 profit rises 33% to Rs85 crore

Standalone total income from operations of Sanofi India rose to Rs608 crore in June quarter as against Rs549.7 crore in the year-ago period New Delhi: Drug firm Sanofi India Ltd on Friday reported a 32.86% rise in standalone net profit to Rs.85.3 ... Livemint.com, 2 days ago
Sanofi Q2 net up 33% at Rs 85 crore Business Standard, 2 days ago
[x]  

902 images for sanofi

Business Standard India, 2 days ago
Moneycontrol.com, 1 day ago
Financial Express, 5 days ago
Reuters UK, 6 days ago
Indian Express, 17 hours ago
American Banking News - Forex, 1 week ago
Share Market Updates, 4 days ago
Livemint.com, 1 week ago
BioSpace, 4 days ago
BioSpace, 4 days ago

Sanofi India fixes record date for interim dividend

Record date is 05 August 2016; Dividend payment date is 16 August 2016
 Business Standard2 days ago Sanofi India declares interim dividend  Money Control2 days ago
India Infoline

Sanofi-Synthelabo unveils 2 new diabetic drugs

Sanofi-Synthelabo (India) Pvt Ltd has launched two drugs for type-2 diabetes patients in India Lyxumia (lixisenatide) and Zemiglo (gemigliptin). Lyxumia, a non-insulin injectable drug, is approved in over 70 countries and commercially launched in most EU ...
 The Hindu5 days ago Sanofi launches diabetes drugs, Lyxumia and Zemiglo in India  PharmaBiz5 days ago Sanofi India expands diabetes portfolio  Express Pharma5 days ago FDA Advisory Committee recommends approval of Sanofi treatment for adults with Type 2 Diabetes  India Infoline1 month ago
[x]  

Warming climate puts more Pinoys at greater risk for dengue

By: , July 23rd, 2016 12:14 AM Infographics provided by sanofi-aventis Philippines The World Health Organization regards dengue as the world's most dominant mosquito-borne viral disease with incident rates that have increased 30-fold in the past ...
 Philippine Daily Inquirer2 days ago

Board of Sanofi India recommends dividend

This page uses frames, but your browser doesn't
 Capital Market2 days ago

BRIEF-Sanofi Enzyme says Ontario adds LEMTRADA to exceptional access program for eligible patients

July 21 Sanofi SA: * Ontario adds Lemtrada (Alemtuzumab) to exceptional access program for eligible patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780) Our top photos from the last 24 hours. ...
 Reuters UK3 days ago Manitoba makes LEMTRADA┬« (alemtuzumab) available to eligible patients with relapsing-remitting MS  BioSpace3 days ago Ontario adds LEMTRADA┬« (alemtuzumab) to the Exceptional Access Program for eligible patients  BioSpace3 days ago Sanofi Genzyme Begins Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Patients with Acid Sphingomyelinase Deficiency  Pharmacy Choice4 days ago
[x]  

Perspectives in diabetes care [Infographic]

(BPT) - - A survey conducted by the American Association of Clinical Endocrinologists (AACE), with support from Sanofi US, found differences in perception between adults living with type 2 diabetes as well as physicians and other medical ...
 Houston Chronicle4 days ago
[x]  
Reuters UK

Sanofi offers EU concessions over Boehringer consumer healthcare deal

French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016. Reuters/Philippe Wojazer/File Photo BRUSSELS - French drugmaker Sanofi ( SASY.PA ) has sought to address EU antitrust ...
 Reuters UK6 days ago Exclusive - Medivation discusses potential sale to Sanofi: sources  Business Standard2 weeks ago Medivation agrees to open its books to Sanofi  Reuters2 weeks ago Sanofi racalls 3 batches of Combiflam; stock up marginally  India Infoline2 months ago
[x]  
Financial Express

Sanofi-Synthelabo India launches 2 diabetes drugs

Drug firm Sanofi-Synthelabo India has expanded Sanofi's diabetes portfolio in the country with launch of two drugs - Lyxumia and Zemiglo - for lowering blood sugar levels. While Lyxumia is a once daily, non-insulin injectable drug, Zemiglo is a ...
 Business Standard5 days ago FDA staff question usefulness of Sanofi diabetes drugs  Reuters2 months ago
[x]  

Sanofi

1. To license Fortune articles, excerpts, or headlines for republication in various media (including books, eBooks, film, web, newsletters, newspapers, magazines and others), please email syndication@timeinc.com. 2. To license a Fortune cover, ...
 Fortune6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sanofi
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less